MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Biogen Inc

Suletud

SektorTervishoid

117.64 0.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

117.05

Max

119.98

Põhinäitajad

By Trading Economics

Sissetulek

-122M

267M

Müük

-15M

2.5B

P/E

Sektori keskmine

10.42

57.333

Aktsiakasum

3.44

Kasumimarginaal

10.865

Töötajad

7,605

EBITDA

-158M

536M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+51.84% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-4.2B

17B

Eelmine avamishind

117.14

Eelmine sulgemishind

117.64

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. mai 2024, 15:56 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

51.84% tõus

12 kuu keskmine prognoos

Keskmine 181.46 USD  51.84%

Kõrge 265 USD

Madal 121 USD

Põhineb 29 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

29 ratings

14

Osta

15

Hoia

0

Müü

Tehniline skoor

By Trading Central

118.83 / 119.99Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.